menu
    • menu

    Company profile for Lee Pharma

    Mix Gif-PSE
    News
    September is Gynecologic Cancer Awareness Month

    07 Sep 2022

    // PRESS RELEASE

    Clay Ganesha Idols Distributed at Lee Pharma Units

    31 Aug 2022

    // PRESS RELEASE

    Lee Pharma celebrated the 76th Independence Day

    16 Aug 2022

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    CPhI WW Frankfurt

    Booth #11.1C68

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Related CompaniesRelated Companies

    About

    Lee Pharma Ltd, established in 1997, is a research-driven pharmaceutical company focused on developing, synthesizing, and commercializing high-quality APIs, intermediates, and finished formulations. We manufacture APIs, pellets, granules, and finished dosage forms using innovative, cost-effective processes. Our world-class manufacturing facilities are certified with USFDA, EU GMP, WHO GMP, ISO 9001:2008, and ISO 14001:2004, meeting the highest international standards. With a commitment to excellence, global reach, and consistent regulatory compliance, we serve healthcare markets across more than 50 countries.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lee Pharmaindia-flag Flag
    Country
    Country
    India
    Address
    Address
    SY. No. : 257 & 258/1, Door No : 11-6/56-C, Opp : IDPL Factory, Moosapet, Bala...
    Telephone
    Telephone
    +91 4023770338
    Client Email
    Email
    sales@leepharma.com
    Client Website
    Website
    http://www.leepharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/lee-pharma-ltd/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Booth #11.1C68

    envelop Contact Supplier

    CPhI WW Frankfurt

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/lee-pharma-party-content-8314.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/lee-pharma-party-content-65786.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2027

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

    #PharmaFlow by PHARMACOMPASS
    15 May 2025
    Share Share
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 8295

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    September is Gynecologic Cancer Awareness Month
    September is Gynecologic Cancer Awareness Month

    07 Sep 2022

    // PRESS RELEASE

    https://www.leepharma.com/post/september-is-gynecologic-cancer-awareness-month-what-everyone-should-know

    PRESS RELEASE
    07 Sep 2022
    Share Share
    Clay Ganesha Idols Distributed at Lee Pharma Units
    Clay Ganesha Idols Distributed at Lee Pharma Units

    31 Aug 2022

    // PRESS RELEASE

    https://www.leepharma.com/post/clay-ganesha-idols-distributed-at-lee-pharma-units-to-protect-the-environment

    PRESS RELEASE
    31 Aug 2022
    Share Share
    Lee Pharma celebrated the 76th Independence Day
    Lee Pharma celebrated the 76th Independence Day

    16 Aug 2022

    // PRESS RELEASE

    https://www.leepharma.com/post/76th-independence-day-celebrated-with-patriotic-fervour-and-colour

    PRESS RELEASE
    16 Aug 2022
    Share Share
    Meno-D, A Novel Formulation For The Treatment Of PCOS.
    Meno-D, A Novel Formulation For The Treatment Of PCOS.

    10 Aug 2022

    // PRESS RELEASE

    https://www.leepharma.com/post/meno-d-a-novel-formulation-for-the-treatment-of-pcos

    PRESS RELEASE
    10 Aug 2022
    Share Share
    Menocycle Softgel Capsule launched
    Menocycle Softgel Capsule launched

    01 Apr 2022

    // PRESS RELEASE

    https://www.leepharma.com/post/menocycle-softgel-capsule-launched

    PRESS RELEASE
    01 Apr 2022
    Share Share
    Lee Health develops Enzymeact to treat digestive disorders
    Lee Health develops Enzymeact to treat digestive disorders

    11 Nov 2021

    // PRESS RELEASE

    https://www.leepharma.com/post/lee-health-develops-enzymeact-to-treat-digestive-disorders

    PRESS RELEASE
    11 Nov 2021
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

    Details:

    Undisclosed


    Lead Product(s): Fentanyl,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Controlled Substance

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 01, 2025

    Company Banner

    01

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Fentanyl,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    May 01, 2025

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer

    Details:

    Undisclosed


    Lead Product(s): Socazolimab,Cisplatin,Carboplatin,Paclitaxel,Bevacizumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 14, 2024

    Company Banner

    02

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Socazolimab,Cisplatin,Carboplatin,Paclitaxel,Bevacizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cer...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Inapplicable

    June 14, 2024

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment

    Details:

    Undisclosed


    Lead Product(s): AU409,Inapplicable

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Undisclosed

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 18, 2024

    Company Banner

    03

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : AU409,Inapplicable

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    April 18, 2024

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Windtree Announces License Agreement with Lee’s Pharmaceuticals for Istaroxime

    Details:

    Under the agreement, Lee will develop and commercialize Windtree’s PST2744 (istaroxime), a first-in-class therapy for acute heart failure and cardiogenic shock in Greater China.


    Lead Product(s): Istaroxime,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Other Small Molecule

    Recipient: Windtree Therapeutics

    Deal Size: $138.1 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 17, 2024

    Company Banner

    04

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Istaroxime,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Recipient : Windtree Therapeutics

    Deal Size : $138.1 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Windtree Announces License Agreement with Lee’s Pharmaceuticals for Istaroxime

    Details : Under the agreement, Lee will develop and commercialize Windtree’s PST2744 (istaroxime), a first-in-class therapy for acute heart failure and cardiogenic shock in Greater China.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    January 17, 2024

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Co...

    Details:

    Undisclosed


    Lead Product(s): Aminolevulinic Acid HCl,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 07, 2023

    Company Banner

    05

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Aminolevulinic Acid HCl,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride ...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    December 07, 2023

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

    Details:

    Undisclosed


    Lead Product(s): Mizoribine,Inapplicable

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 02, 2023

    Company Banner

    06

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Mizoribine,Inapplicable

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplant...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    November 02, 2023

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer

    Details:

    Undisclosed


    Lead Product(s): Recombinant Human Interferon Alpha-2b,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Undisclosed

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 10, 2023

    Company Banner

    07

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Recombinant Human Interferon Alpha-2b,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of t...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    April 10, 2023

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

    Details:

    Undisclosed


    Lead Product(s): Fentanyl,Inapplicable

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Controlled Substance

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 08, 2022

    Company Banner

    08

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Fentanyl,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BT...

    Details : Undisclosed

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    September 08, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

    Details:

    Under terms of the global license agreement, Lee’s and Zhaoke will receive a global license to develop and commercialize Surfaxin®, lyophilized lucinactant and AEROSURF (lucinactant) for any potential indications and applications.


    Lead Product(s): Lucinactant,Inapplicable

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Aerosurf

    Study Phase: Phase IIProduct Type: Peptide

    Recipient: Windtree Therapeutics

    Deal Size: $78.9 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 23, 2022

    Company Banner

    09

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Lucinactant,Inapplicable

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase II

    Recipient : Windtree Therapeutics

    Deal Size : $78.9 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement

    Details : Under terms of the global license agreement, Lee’s and Zhaoke will receive a global license to develop and commercialize Surfaxin®, lyophilized lucinactant and AEROSURF (lucinactant) for any potential indications and applications.

    Product Name : Aerosurf

    Product Type : Peptide

    Upfront Cash : Undisclosed

    August 23, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-L...

    Details:

    ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.


    Lead Product(s): Socazolimab,Carboplatin,Etoposide

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody

    Sponsor: Sorrento Therapeutics

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 17, 2022

    Company Banner

    10

    Lee Pharma

    India
    arrow
    CPhI WW Frankfurt
    Booth #11.1C68
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothLee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

    Lead Product(s) : Socazolimab,Carboplatin,Etoposide

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Sorrento Therapeutics

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III ...

    Details : ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.

    Product Name : Undisclosed

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 17, 2022

    Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact LEE PHARMA LTD and get a quotation

    LEE PHARMA LTD is a supplier offers 85 products (APIs, Excipients or Intermediates).

    Find a price of Bilastine bulk with DMF, JDMF offered by LEE PHARMA LTD

    Find a price of Esomeprazole Magnesium bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Lacosamide bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Lansoprazole bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Olanzapine bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Omeprazole bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Pantoprazole Sodium bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Rosuvastatin Calcium bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Sertraline Hydrochloride bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Varenicline Tartrate bulk with DMF, JDMF offered by LEE PHARMA LTD

    Find a price of Voriconazole bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Rivaroxaban bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Sitagliptin Phosphate bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Ticagrelor bulk with DMF, CEP offered by LEE PHARMA LTD

    Find a price of Apixaban bulk with DMF offered by LEE PHARMA LTD

    Find a price of Bempedoic Acid bulk with DMF offered by LEE PHARMA LTD

    Find a price of Brivaracetam bulk with DMF offered by LEE PHARMA LTD

    Find a price of Cariprazine Hydrochloride bulk with DMF offered by LEE PHARMA LTD

    Find a price of Dabigatran Etexilate Mesylate bulk with DMF offered by LEE PHARMA LTD

    Find a price of Dapagliflozin bulk with DMF offered by LEE PHARMA LTD

    Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF offered by LEE PHARMA LTD

    Find a price of Empagliflozin bulk with DMF offered by LEE PHARMA LTD

    Find a price of Esomeprazole Magnesium bulk with CEP offered by LEE PHARMA LTD

    Find a price of Esomeprazole Sodium bulk with CEP offered by LEE PHARMA LTD

    Find a price of Itraconazole bulk with DMF offered by LEE PHARMA LTD

    Find a price of Linezolid bulk with DMF offered by LEE PHARMA LTD

    Find a price of Lurasidone Hydrochloride bulk with DMF offered by LEE PHARMA LTD

    Find a price of Mirogabalin Besylate bulk with DMF offered by LEE PHARMA LTD

    Find a price of Relugolix bulk with DMF offered by LEE PHARMA LTD

    Find a price of Resmetirom bulk with DMF offered by LEE PHARMA LTD

    Find a price of Tegoprazan bulk with DMF offered by LEE PHARMA LTD

    Find a price of Tofacitinib Citrate bulk with DMF offered by LEE PHARMA LTD

    Find a price of Vildagliptin bulk with DMF offered by LEE PHARMA LTD

    Find a price of Dexlansoprazole bulk with DMF offered by LEE PHARMA LTD

    Find a price of Finerenone bulk with DMF offered by LEE PHARMA LTD

    Find a price of Linagliptin bulk with DMF offered by LEE PHARMA LTD

    Find a price of Raltegravir Potassium bulk with DMF offered by LEE PHARMA LTD

    Find a price of Sacubitril-Valsartan bulk with DMF offered by LEE PHARMA LTD

    Find a price of Sitagliptin Phosphate bulk with DMF offered by LEE PHARMA LTD

    Find a price of Tamsulosin bulk with CEP offered by LEE PHARMA LTD

    Find a price of Upadacitinib bulk with DMF offered by LEE PHARMA LTD

    Find a price of Viloxazine Hydrochloride bulk with DMF offered by LEE PHARMA LTD

    Find a price of Voriconazole bulk with CEP offered by LEE PHARMA LTD

    Find a price of Esomeprazole Magnesium bulk offered by LEE PHARMA LTD

    Find a price of Ferric Maltol bulk offered by LEE PHARMA LTD

    Find a price of Lobeglitazone bulk offered by LEE PHARMA LTD

    Find a price of Moxifloxacin Hydrochloride bulk offered by LEE PHARMA LTD

    Find a price of Pantoprazole Sodium bulk offered by LEE PHARMA LTD

    Find a price of Pregabalin bulk offered by LEE PHARMA LTD

    Find a price of Rosuvastatin Calcium bulk offered by LEE PHARMA LTD

    Find a price of Sitagliptin Hydrochloride bulk offered by LEE PHARMA LTD

    Find a price of Alogliptin Benzoate bulk offered by LEE PHARMA LTD

    Find a price of Baricitinib bulk offered by LEE PHARMA LTD

    Find a price of Cenobamate bulk offered by LEE PHARMA LTD

    Find a price of Dapagliflozin Propanediol Monohydrate bulk offered by LEE PHARMA LTD

    Find a price of Elagolix Sodium bulk offered by LEE PHARMA LTD

    Find a price of Empagliflozin bulk offered by LEE PHARMA LTD

    Find a price of Fenofibrate bulk offered by LEE PHARMA LTD

    Find a price of Ferric Carboxymaltose bulk offered by LEE PHARMA LTD

    Find a price of Finerenone bulk offered by LEE PHARMA LTD

    Find a price of Ibandronate Sodium bulk offered by LEE PHARMA LTD

    Find a price of Itraconazole bulk offered by LEE PHARMA LTD

    Find a price of Ivabradine Hydrochloride bulk offered by LEE PHARMA LTD

    Find a price of Lenacapavir bulk offered by LEE PHARMA LTD

    Find a price of Linagliptin bulk offered by LEE PHARMA LTD

    Find a price of Linezolid bulk offered by LEE PHARMA LTD

    Find a price of Mirogabalin Besylate bulk offered by LEE PHARMA LTD

    Find a price of Montelukast Sodium bulk offered by LEE PHARMA LTD

    Find a price of Omeprazole bulk offered by LEE PHARMA LTD

    Find a price of Omeprazole Magnesium bulk offered by LEE PHARMA LTD

    Find a price of Pantoprazole Magnesium bulk offered by LEE PHARMA LTD

    Find a price of Posaconazole bulk offered by LEE PHARMA LTD

    Find a price of Prasugrel Hydrochloride bulk offered by LEE PHARMA LTD

    Find a price of Rabeprazole Sodium bulk offered by LEE PHARMA LTD

    Find a price of Roxadustat bulk offered by LEE PHARMA LTD

    Find a price of Ruxolitinib Phosphate bulk offered by LEE PHARMA LTD

    Find a price of Saxagliptin bulk offered by LEE PHARMA LTD

    Find a price of Silodosin bulk offered by LEE PHARMA LTD

    Find a price of Suvorexant bulk offered by LEE PHARMA LTD

    Find a price of Suzetrigine bulk offered by LEE PHARMA LTD

    Find a price of Tamsulosin bulk offered by LEE PHARMA LTD

    Find a price of Tegoprazan bulk offered by LEE PHARMA LTD

    Find a price of Teneligliptin Hydrobromide bulk offered by LEE PHARMA LTD

    Find a price of Vildagliptin bulk offered by LEE PHARMA LTD

    Find a price of Xanomeline bulk offered by LEE PHARMA LTD

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search